Cargando…
Cystadenocarcinoma of the parotid: case report of a BRAF inhibitor treatment
BACKGROUND: Mutations of the proto-oncogene BRAF have been described in many cancers. Mutated BRAF causes overactive downstream signaling via MEK and ERK leading to excessive cell proliferation and survival. Their identification is of real interest because specific inhibitors have been developed. ME...
Autores principales: | Boyrie, Sabrina, Fauquet, Isabelle, Rives, Michel, Genebes, Caroline, Delord, Jean-Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872282/ https://www.ncbi.nlm.nih.gov/pubmed/24386625 http://dx.doi.org/10.1186/2193-1801-2-679 |
Ejemplares similares
-
High-grade Features of Papillary Cystadenocarcinoma of the Parotid Gland
por: Wang, Kevin Y., et al.
Publicado: (2019) -
Cytomorphological features of papillary cystadenocarcinoma of parotid gland: A case report with review of literature
por: Joshi, Usha, et al.
Publicado: (2016) -
Papillary cystadenocarcinoma of the parotid gland: a rare sub-variant of salivary gland adenocarcinoma
por: Dutta, Satya, et al.
Publicado: (2022) -
Dosimetric comparison between helical tomotherapy and volumetric modulated arc-therapy for non-anaplastic thyroid cancer treatment
por: Khalifa, Jonathan, et al.
Publicado: (2014) -
Case Report: Complete Response of Recurrent and Metastatic Cystadenocarcinoma of the Parotid Gland With a Single Course of Combined Nivolumab and Ipilimumab Therapy
por: Nakamura, Yoshiyuki, et al.
Publicado: (2021)